The DOI matches its Crossref record, with a small difference in title or year; 108 of the 108 references it cites were found in a registry or an index.
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Abstract
BACKGROUND: To characterize further behavioral, cognitive, neuroendocrine, and physiological effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects. Ketamine, a phencyclidine hydrochloride derivative, is a dissociative anesthetic and a noncompetitive antagonist of the N-methyl-D-aspartate subtype of excitatory amino acid receptor. METHODS: Nineteen healthy subjects recruited by advertisements from the community participated in this randomized, double-blind, placebo-controlled study. Subjects completed three test days involving the 40-minute intravenous administration of placebo, ketamine hydrochloride (0.1 mg/kg), or ketamine hydrochloride (0.5 mg/kg). Behaviors associated with the positive and negative symptoms of schizophrenia were assessed by using the Brief Psychiatric Rating Scale. Changes in perception and behaviors associated with dissociative states were assessed by the Perceptual Aberration Subscale of the Wisconsin Psychosis Proneness Scale and the Clinician-Administered Dissociative States Scale. Cognitive function was assessed by using the (1) Mini-Mental State Examination; (2) tests sensitive to frontal cortical dysfunction, including a continuous performance vigilance task, a verbal fluency task, and the Wisconsin Card Sorting Test; and (3) tests of immediate and delayed recall. Plasma levels of cortisol, prolactin, homovanillic acid, and 3-methoxy-4-hydroxyphenethyleneglycol were measured. RESULTS: Ketamine (1) produced behaviors similar to the positive and negative symptoms of schizophrenia; (2) elicited alterations in perception; (3) impaired performance on tests of vigilance, verbal fluency, and the Wisconsin Card Sorting Test; (4) evoked symptoms similar to dissociative states; and (5) preferentially disrupted delayed word recall, sparing immediate recall and postdistraction recall. Ketamine had no significant effect on the Mini-Mental State Examination at the doses studied. Ketamine also had no effect on plasma 3-methoxy-4-hydroxyphenethyleneglycol levels, although it blunted a test day decline in plasma homovanillic acid levels at the higher dose. It also dose dependently increased plasma cortisol and prolactin levels. Ketamine produced small dose-dependent increases in blood pressure. CONCLUSIONS: These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is evidence that NMDAR antagonism is responsible for ketamine’s dissociative and psychotomimetic effects”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Krystal et al., 1994
In the citing paper
“Based on studies that detail the onset of drug-induced effects in humans, ketamine (0.5 mg/kg i.v. over 40 minutes) produces illusory experiences, increases in perceptual acuity, and paranoia within 10 minutes of treatment initiation, which supports rapid brain entry of ketamine in humans”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Krystal et al., 1994
In the citing paper
“Indeed, whereas responses to trauma have been linked to the noradrenergic system (Bremner et al., 1996a(Bremner et al., , 1996b;;Krystal et al., 1989), ketamine (a glutamate (NMDA) receptor antagonist) has been shown to induce detachment and withdrawal as well as sensory distortions and illusions (Krystal et al., 1994).”
From A review of the relation between dissociation, memory, executive functioning and social cognition in military members and civilians with neuropsychiatric conditions (2016) · cites this paper as Krystal et al., 1994
In the citing paper
“Ketamine is a dissociative psychedelic, which acts as NMDAR (N-methyl-D-aspartate receptor) antagonists, effectively engaging the glutamatergic system [31].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [31]
In the citing paper
“The hypothesis that NMDAR hypofunction might be a pathogenic trigger for schizophrenia 9,10 arose from observations that administration of the dissociative anesthetics phencyclidine and ketamine to healthy subjects mimicked the primary symptoms of schizophrenia 11,12 coupled with the finding that these compounds are NMDAR antagonists 13 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1967) · Medical Entomology and Zoology · Cited by 7,532
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Morris, R. G. M., Anderson, E., Lynch, G. S., & Baudry, M. (1986) · Nature · doi:10.1038/319774a0 · Cited by 3,640
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,019
Negative v Positive Schizophrenia: Definition and Validation
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,012
Cited by
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165
Metadata
- Authors
- Krystal, J. H.
- Affiliations
- Veterans Health Administration (US)
- Corresponding author
- Krystal, John H.
- ORCID
- Krystal, John H.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1994-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 199
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2028884770
- Cited by
- 3,330
- References
- 107
- Citations by year
- 2026: 55 · 2025: 103 · 2024: 104 · 2023: 102 · 2022: 133 · 2021: 138 · 2020: 149 · 2019: 134 · 2018: 132 · 2017: 147 · 2016: 160 · 2015: 175 · 2014: 159 · 2013: 168 · 2012: 122
- FWCI
- 29.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30929)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Developmental Neuroscience › Anesthesia and Neurotoxicity Research
- Keywords
- ketamine, subanesthetic doses, NMDA receptor antagonists, schizophrenia symptoms, dissociative states, cognitive impairment, frontal lobe dysfunction, plasma cortisol, prolactin, homovanillic acid, blood pressure
- MeSH terms
- Adult, Blood Pressure, Cognition, Dissociative Disorders, Dose-Response Relationship, Drug, Double-Blind Method, Female, Frontal Lobe, Homovanillic Acid, Humans, Hydrocortisone, Ketamine, Male, Methoxyhydroxyphenylglycol, Neuropsychological Tests, Perception, Prolactin, Psychiatric Status Rating Scales, Psychoses, Substance-Induced, Pulse, Schizophrenia, Schizophrenic Psychology, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. https://app.cochat.ai/papers/10.1001/archpsyc.1994.03950030035004
- The paper
- Krystal, J. H. (1994). Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1994.03950030035004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.